Trial Profile
A Phase III Randomized 1:1, Masked, Study of the Safety, Tolerability, and Efficacy of Intravitreal Pre-op 0.3mg Pegaptanib Sodium Versus Sham, for Adjuvant Management of TRD and Vit Hem Associated With PDR
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 02 May 2014
Price :
$35
*
At a glance
- Drugs Pegaptanib (Primary)
- Indications Diabetic retinopathy
- Focus Therapeutic Use
- Acronyms NO-CRUNCH01
- 04 Mar 2014 According to ClinicalTrials.gov record trial status changed from recruiting to withdrawn prior to recruitment.
- 09 May 2012 New trial record